Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

GT Biopharma, Inc. GTBP

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
0.00%

Capital & Financial Ratios

Market Cap
13.51
Revenue
0.06
Net Income
(4.76)
Free Cash Flow
(14.43)
Net Debt
(5.05)
Current Ratio
2.61
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
185.30
P/B ratio
3.12
Past 5Y EPS Growth
54.16%
This Y EPS Growth
93.56%
Next Y EPS Growth
25.58%
Next 5Y EPS Growth
65.26%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2019 ‡‡‡
2018 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 13.97 4.04 6.91 5.05
Receivables — — — —
Inventory — — — —
Other — — 0.63 0.51
14.06 4.23 8.11 5.79
2023 2024 2025 Q'26
Payables 4.33 3.85 0.75 1.02
ST’ Debt — — — —
Other 1.05 0.25 0.01 —
6.63 5.90 2.32 2.22
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡ ‡‡‡‡‡

Revenue

Year
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (2.47) (4.26) — —
—
’25 (2.20) (3.01) (3.68) (4.02)
(12.91)
’24 (4.16) (3.54) (2.74) (2.47)
(12.90)
’23 (2.91) (1.93) (1.96) (2.05)
(8.85)
’22 (5.21) (2.79) (2.92) (4.30)
(15.22)
’21 (3.68) (4.29) (3.93) (3.70)
(15.61)
’20 (0.22) (3.41) (1.70) (1.93)
(7.26)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (2.47) (4.26) — —
—
’25 (2.20) (3.01) (3.68) (4.02)
(12.91)
’24 (4.16) (3.54) (2.74) (2.47)
(12.90)
’23 (2.91) (1.93) (1.96) (2.05)
(8.85)
’22 (5.21) (2.79) (2.92) (4.30)
(15.22)
’21 (3.68) (4.29) (3.93) (3.70)
(15.61)
’20 (0.22) (3.41) (1.70) (1.93)
(7.26)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (2.75) (3.00) — —
—
’25 (8.25) (13.75) (20.75) (121.00)
(167.00)
’24 (41.00) (54.25) (38.25) (41.50)
(173.50)
’23 (7.51) (37.54) (45.04) —
(141.00)
’22 (127.63) (75.07) (165.16) (135.13)
(495.50)
’21 (1.37k) (112.61) (127.63) (390.39)
(1.55k)
’20 (255.36) (1.53k) (510.71) (2.86)
(4.84k)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 26.28 5.40 1.72 0.54 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 112.20 33.00 10.66 3.85 — — —
High Price
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 2 2 1 1 — — —
Employees
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 — — —
Revenue/Emp
— — — — — — — — — — — — —
Revenue
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ — — — — — — — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.88) (7.60) (13.16) (28.35) — — —
EBT
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (20.88) (7.60) (13.16) (28.35) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — — — — — — — —
Depreciation
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (495.50) (141.00) (173.50) (167.00) ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (358.05) (164.23) (170.01) (58.57) — — —
Cash Flow/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (358.05) (164.23) (170.01) (58.57) — — —
Free CF/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 276.09 138.70 (22.00) 26.24 — — —
Book Value/Sh
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.04 0.05 0.08 0.22 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — — — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — — — — — — — — — ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — — — — — — — — — — — —
EV/Sales
— — — — — — — — — — — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.22) (8.85) (12.90) (12.91) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — — — — — — — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15.22) (8.85) (12.90) (12.91) — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.62 7.42 (1.67) 5.79 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.17 — — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (16.33) (13.97) (4.04) (6.90) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.73 7.48 (1.67) 5.79 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (85.41%) (49.26%) (143.53%) (558.42%) — — —
ROA
‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00% 0.00% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (124.15%) (79.10%) (453.55%) (1,674.31%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

GT Biopharma (GTBP) leads with its TriKE platform, harnessing NK cells for solid tumors and blood cancers, positioning it as a high-risk, high-reward immuno-oncology disruptor in a $50B+ NK therapy market. Despite zero revenue and R&D-driven losses peaking at -$259M in 2018, financials have stabilized: net income improved 73% since 2020 to -$13.2M in 2023, free cash flow per share eased 86% to -$6.80, debt hit zero, and net cash reached $4M—providing 2-3 years’ runway amid 42% share dilution.

Stock volatility reflects five reverse splits and a 99% drawdown from 2016 peaks, decoupling from shrinking losses and undervaluing GTBP versus peers at 5-10x cash multiples. Unanimous analyst targets signal 1640% upside from recent lows, driven by Phase 1b data for GTB-201 (AML), IND clearance, Takeda collaboration, and NK advantages over CAR-T.

Pipeline catalysts like 2026 Phase 2 readouts could trigger revenue inflection and partnerships, mirroring pre-pivot Moderna dynamics—though binary trial risks and projected 1300% dilution loom. Insider neutrality amid cash builds adds quiet bullishness, tempting a risk-adjusted bet on this oversold biotech breakout.

Read full commentary →

GT Biopharma, Inc. (GTBP) Latest News

News by impact score

Fine-tune

16 Sep

4 , 7:30 AM
GT Biopharma reaches development milestone enabling human trials for its novel blood cancer therapy. Milestone advances GT Biopharma's novel therapy into human trials, likely driving major shifts in company trajectory and investor sentiment.

15 Sep

4 , 8:45 AM
GT Biopharma achieves development milestone for human trial of novel blood cancer therapy. Milestone advances GT Biopharma's lead candidate into clinical testing, likely driving major valuation gains and strategic momentum.

3 , 9:15 AM
GT Biopharma announces potential new indication for GTB-5550, a B7-H3-targeted NK cell engager, for multiple myeloma. New indication expands GTB-5550 addressable market and supports pipeline development.

1 Jun

4 Benzinga, 7:31 AM
GT Biopharma achieves faster drug discovery and productivity gains after rolling out AI technology. AI rollout directly accelerates core R&D processes at GT Biopharma and can materially improve competitive positioning.

3 GlobeNewswire, 8:00 AM
GT Biopharma updates its pipeline discovery activities using newly implemented AI-based technological initiatives. GT Biopharma's use of AI for pipeline discovery may improve drug innovation efficiency with moderate effects on future performance.

15 May

3 GlobeNewswire, 8:00 AM
GT Biopharma, Inc. (GTBP) reported first quarter 2026 financial results. Quarterly financial results affect key financial performance metrics and investor sentiment.

3 GlobeNewswire, 9:00 AM
GT Biopharma, Inc. has appointed Andrew Ritter to its Board of Directors, replacing Dr. Rajesh Shrotriya, who is resigning. Ritter brings over 20 years of experience in biotechnology and healthcare technology, currently serving as CEO of Cairns Health and previously leading Docbot and Ritter Pharmaceuticals. His expertise is expected to be valuable as GT Biopharma advances its NK cell engager platform through clinical trials. The appointment of a seasoned biotech executive may moderately influence GT Biopharma's strategic direction and operational effectiveness.

14 May

4 GlobeNewswire, 8:30 AM
GT Biopharma dosed the first patient in the Phase 1 trial of GTB-5550, a B7-H3-targeted natural killer cell engager for solid tumors. Dosing the first patient in a Phase 1 trial advances GT Biopharma's oncology pipeline significantly, likely enhancing investor sentiment and stock trajectory.

4 Benzinga, 8:16 AM
GT Biopharma initiates testing of its lead solid tumor drug candidate across multiple cancer types. Beginning tests of the lead solid tumor drug across multiple cancers marks a major pipeline expansion that could significantly drive GTBP's clinical progress and investor interest.

3 GlobeNewswire, 7:00 AM
GT Biopharma, Inc. has appointed Hilary Kramer to its Board of Directors, replacing Bruce Wendel, who is resigning. Michael Breen, Executive Chairman and CEO, expressed enthusiasm for Kramer's expertise as the company advances its NK engagers. Kramer is the Founder and Chief Investment Officer of GreenTech Research and has extensive experience on various public company boards and in investment management. GT Biopharma focuses on developing immuno-oncology therapeutics using its proprietary TriKE® platform, which enhances the immune system's natural killer cells. The appointment of Hilary Kramer is expected to moderately influence GT Biopharma's strategic direction and operational effectiveness.

16 Mar

4 Zacks, 12:00 PM
GT Biopharma (GTBP) upgraded to Buy rating by analysts, citing promising clinical pipeline, strategic partnerships, and undervalued stock potential amid biotech sector recovery. Analyst upgrade to Buy highlights strong clinical progress and undervaluation, likely driving significant stock gains and investor interest.

2 Mar

3 GlobeNewswireMobyMobyZacksGuruFocus.comMarketBeatGuruFocus.com, 7:00 AM
GT Biopharma, Inc. (GTBP) reported full year 2025 financial results. Full-year financial results disclosure affects financial performance and investor sentiment moderately.

3 Feb

4 GlobeNewswire, 8:30 AM
GT Biopharma, Inc. has received FDA clearance for its Investigational New Drug (IND) application for GTB-5550 TriKE®, a novel therapy targeting B7-H3 in solid tumors. This approval allows the company to initiate clinical trials, marking a significant step in the development of its NK cell engager technology aimed at improving cancer treatment outcomes. FDA clearance for clinical trials represents a major strategic advancement in GT Biopharma's product pipeline.

15 Jan

4 GlobeNewswire, 8:30 AM
GT Biopharma, Inc. has submitted an Investigational New Drug (IND) application for GTB-5550 TriKE®, a novel therapeutic designed to target B7-H3 in natural killer (NK) cells for the treatment of solid tumors expressing this antigen. This submission marks a significant step in the development of targeted cancer therapies aimed at improving patient outcomes in challenging-to-treat cancers. The IND submission for GTB-5550 TriKE® represents a major strategic move that could significantly impact the company's future performance and investor sentiment.

8 Dec

4 www.thestreet.com, 4:28 PM
GT Biopharma, Inc. CEO discusses advancements in humane cancer treatment during a podcast, highlighting the company's innovative approaches and potential impact on patient care. The conversation covers the science behind their therapies and the importance of ethical considerations in cancer treatment, aiming to improve outcomes while minimizing side effects. Innovative approaches to cancer treatment could significantly alter the company's trajectory and investor sentiment.

19 Nov

4 ACCESS NewswireGuruFocus.comMotley FoolSimply Wall St.GuruFocus.comSimply Wall St.GuruFocus.comSimply Wall St., 8:00 AM
GT Biopharma, Inc. (NASDAQ:GTBP) is advancing its Phase 1 clinical trials, presenting a near-term catalyst opportunity for investors. The company is focused on developing innovative therapies for cancer treatment, and the progress in these trials could significantly influence its market position and investor sentiment. As the trials move forward, stakeholders are closely monitoring the outcomes, which may lead to further developments in the company's product pipeline. Advancing Phase 1 trials could significantly impact GT Biopharma's market position and investor sentiment.

14 Nov

4 GlobeNewswire, 4:00 PM
GT Biopharma, Inc. reports third quarter 2024 financial results, including progress on TriKE® platform and cash position. Significant impact expected on future and performance due to progress on TriKE® platform and financial results.

3 GlobeNewswireGuruFocus.comGuruFocus.com, 9:00 AM
GT Biopharma, Inc. (GTBP) reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its corporate strategy. The company provided updates on ongoing projects and future plans, emphasizing its commitment to advancing its pipeline and enhancing shareholder value. Financial performance indicators showed trends that may influence investor sentiment and market positioning. Financial results and corporate updates indicate moderate influence on the company's future performance and market positioning.

23 Oct

4 GlobeNewswire, 9:00 AM
GT Biopharma, Inc. announced an enrollment update for its Phase 1 trial of GTB-3650, targeting patients with relapsed or refractory CD33 expressing hematologic malignancies. The trial aims to evaluate the safety and efficacy of GTB-3650, a novel immunotherapy designed to treat these specific cancers. The company is actively recruiting participants to advance the study and assess the treatment's potential benefits. The Phase 1 trial's progress and potential outcomes could significantly influence GT Biopharma's market position and investor sentiment.

8 Oct

4 , 9:00 AM
GT Biopharma, Inc. announced an enrollment update for its Phase 1 trial of GTB-3650, targeting patients with relapsed or refractory CD33 expressing hematologic malignancies. The trial aims to evaluate the safety and efficacy of GTB-3650, a novel immunotherapy designed to treat these specific cancers. The company is actively recruiting participants and is optimistic about the trial's progress and potential outcomes. The Phase 1 trial's progress and potential outcomes could significantly influence GT Biopharma's market position and investor sentiment.

4 , 8:31 AM
GT Biopharma, Inc. has reported progress in its Phase 1 trial for its lead drug candidate targeting blood cancers. The trial aims to evaluate the safety and efficacy of the treatment, which has shown promising initial results. The company is optimistic about the potential of this drug to address unmet medical needs in the oncology space, and further updates are anticipated as the trial progresses. The advancement in the Phase 1 trial could significantly impact GT Biopharma's future performance and investor sentiment.

6 Oct

3 , 9:00 AM
GT Biopharma, Inc. will participate in the Centurion One Capital 3rd Annual Bahamas Summit, highlighting its commitment to engaging with investors and stakeholders in the biopharmaceutical sector. The event is expected to provide a platform for discussing the company's strategic initiatives and advancements in its pipeline. Participation in investor summits can enhance visibility and stakeholder engagement, potentially influencing market sentiment.

14 Aug

3 GlobeNewswire, 4:05 PM
GT Biopharma, Inc. (GTBP) reported its financial results for the second quarter of 2025, highlighting key metrics such as revenue, expenses, and net income. The company continues to focus on its pipeline of therapeutic candidates and strategic initiatives aimed at enhancing shareholder value. Management provided insights into ongoing projects and future outlook, emphasizing commitment to innovation and market expansion. Financial results and strategic initiatives may moderately influence the company's performance and market sentiment.

11 Aug

4 , 7:00 AM
GT Biopharma, Inc. has progressed into Cohort 3 of its Phase 1 trial for GTB-3650 after a safety review of Cohort 2 showed no significant adverse effects. This advancement indicates positive safety data and supports the ongoing development of the treatment. Advancing to Cohort 3 suggests significant progress in clinical trials, which could enhance investor confidence and impact future market performance.

13 Jun

3 GlobeNewswire, 9:00 AM
GT Biopharma, Inc. has appointed David C. Mun-Gavin to its Board of Directors. Mun-Gavin brings decades of executive leadership experience from global private banks and has served as CEO of the Vanol Group. His expertise is expected to provide valuable guidance as the company approaches its first data readout for GTBP-3650 and aims to expand its NK-engager pipeline in 2026. The appointment of a seasoned executive may moderately influence the company's strategic direction and operational effectiveness.

19 May

4 , 9:00 AM
GT Biopharma, Inc. has successfully advanced its GTB-3650 Phase 1 trial to Cohort 2 after initial human dosing showed promising early immune activation signals. This progress indicates potential efficacy and safety of the treatment, which targets various cancers, and reflects the company's commitment to developing innovative therapies. Advancing to Cohort 2 in a clinical trial suggests significant progress in product development that could enhance the company's market position.

4 Mar

3 , 7:00 AM
GT Biopharma, Inc. will participate in the 10th Anniversary of the Innate Killer Summit, highlighting its commitment to advancing research in immunotherapy and cancer treatment. The event will feature discussions on the latest developments in innate immune cell therapies, which are crucial for the company's focus on innovative cancer treatments. Participation in such a prominent summit underscores GT Biopharma's strategic positioning within the biopharmaceutical industry. Participation in a significant industry summit may enhance visibility and networking opportunities, potentially influencing future collaborations and innovations.

25 Feb

3 GlobeNewswire, 2:00 PM
GT Biopharma, Inc. announced the exercise of warrants for 302,069 shares of common stock at an exercise price of $4.35 per share, generating approximately $0.7 million in gross proceeds. In exchange for immediate cash exercise, the company will issue new unregistered warrants for 604,138 shares at an exercise price of $2.02 per share. The offering is expected to close on February 27, 2025, and proceeds will be used for working capital and corporate purposes. The new warrants will have varying terms, and the company plans to file a registration statement for resale of shares from the new warrants. The exercise of warrants and issuance of new warrants may moderately influence GT Biopharma's financial performance and market sentiment.

27 Jan

4 GlobeNewswire, 7:00 AM
GT Biopharma, Inc. has announced the dosing of the first patient in its Phase 1 clinical trial for GTB-3650, a second-generation TriKE designed to treat hematologic malignancies. This trial aims to evaluate the safety and efficacy of GTB-3650, which is expected to enhance the immune system's ability to target and eliminate cancer cells. The company is optimistic about the potential of this innovative therapy in addressing unmet medical needs in cancer treatment. The initiation of a Phase 1 trial for a promising cancer treatment could significantly impact GT Biopharma's future performance and investor sentiment.

26 Sep

3 GlobeNewswire, 9:15 AM
GT Biopharma, Inc. to participate in a panel discussion on innovative therapies for AML and MDS at the 3rd Annual ROTH Healthcare Opportunities Conference. Participation in conference may moderately influence key areas like product innovation and competitive positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us